Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences.
Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.
Molecular Combing fulfills an unmet medical and research need by enabling the qualitative and quantitative detection of large scale genome changes that are implicated in pathology and are frequently hidden or inaccurately detected by current technologies.
We develop innovative products in partnership with a network of well established research labs, diagnostic and instrument manufacturers with the aim of accelerating product launch to the international market.
We are working in partnerships with key reference laboratories to provide doctors and patients with early access to our in vitro genetic tests. We are also playing an important role in the movement towards personalized medicine by developing tests that help physicians identify how patients are likely to respond to targeted therapies (pharmacogenomics, cellular proliferation.)
As a spin-off from the Pasteur Institute (Paris), Genomic Vision began operation in 2006. Since its inception the company raised €10 million throught two rounds of equity financing from venture capital investors (Société Générale Asset Management and Vesalius Biocapital Partners) and through national and european grants. Genomic Vision’s headquarters and research facilities are located in Paris, France.